PMID- 28742926
OWN - NLM
STAT- MEDLINE
DCOM- 20190422
LR  - 20190422
IS  - 1365-2133 (Electronic)
IS  - 0007-0963 (Linking)
VI  - 178
IP  - 2
DP  - 2018 Feb
TI  - Intravenous immunoglobulin as adjunct therapy for refractory pyoderma 
      gangrenosum: systematic review of cases and case series.
PG  - 363-368
LID - 10.1111/bjd.15850 [doi]
AB  - Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis. Treatment regimens 
      for refractory cases are nonstandardized. Intravenous immunoglobulin (IVIG) is an 
      emerging treatment with reported success, but the efficacy of IVIG for PG is 
      unknown. In this systematic review of cases and case series, we assessed the 
      efficacy of IVIG for the treatment of PG, as observed at our institution and 
      reported in the literature. A retrospective chart review at two tertiary care 
      hospitals between 2000 and 2015, and literature searches in PubMed/MEDLINE, 
      EMBASE and Web of Science from all years were conducted. In total, there were 49 
      patients, including 43 patients from 26 articles and six institutional cases. 
      There was complete or partial response in 43 (88%) patients and complete response 
      in 26 (53%) patients. The mean time to initial response to treatment and 
      treatment length were 3.5 (SD 3.3) weeks and 5.9 (SD 7.8) months, respectively. 
      On average, 2.6 treatments had been trialled before IVIG initiation. IVIG was 
      administered with systemic steroids in 43 (88%) cases. Mild adverse events, 
      especially nausea and headache, were reported in 12 (24.5%) patients. Our 
      systematic review suggests a potential role for IVIG as adjuvant therapy for 
      refractory PG. Prospective clinical trials testing the efficacy of IVIG for 
      refractory PG are needed to validate these findings.
CI  - (c) 2017 British Association of Dermatologists.
FAU - Song, H
AU  - Song H
AUID- ORCID: 0000-0002-9999-4943
AD  - Harvard Medical School, Boston, MA, U.S.A.
FAU - Lahood, N
AU  - Lahood N
AD  - Department of Internal Medicine, Beth Israel Deaconess Medical Center, Boston, 
      MA, U.S.A.
FAU - Mostaghimi, A
AU  - Mostaghimi A
AUID- ORCID: 0000-0002-6084-5617
AD  - Department of Internal Medicine, Beth Israel Deaconess Medical Center, Boston, 
      MA, U.S.A.
AD  - Department of Dermatology, Brigham and Women's Hospital, 75 Francis Street, PBB-B 
      421, Boston, MA, 02115, U.S.A.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20180109
PL  - England
TA  - Br J Dermatol
JT  - The British journal of dermatology
JID - 0004041
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
CIN - Br J Dermatol. 2018 Feb;178(2):317-318. PMID: 29441546
MH  - Adjuvants, Immunologic/*therapeutic use
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Chronic Disease
MH  - Female
MH  - Humans
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Pyoderma Gangrenosum/*drug therapy
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2017/07/26 06:00
MHDA- 2019/04/23 06:00
CRDT- 2017/07/26 06:00
PHST- 2017/07/17 00:00 [accepted]
PHST- 2017/07/26 06:00 [pubmed]
PHST- 2019/04/23 06:00 [medline]
PHST- 2017/07/26 06:00 [entrez]
AID - 10.1111/bjd.15850 [doi]
PST - ppublish
SO  - Br J Dermatol. 2018 Feb;178(2):363-368. doi: 10.1111/bjd.15850. Epub 2018 Jan 9.